Clinical Trials Sponsored by Klus Pharma Inc.

Total 2366 results

Astellas Pharma Global Development, Inc.

Completed

A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT) (EXERRT)

Coronary Artery Disease (CAD)

United States, Peru, Argentina, Puerto Rico
Astellas Pharma Global Development, Inc.

Terminated

Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis (MAGIC-2)

Candidiasis

Philippines, United States, Canada, Israel, Romania, Greece, Turkey, Brazil, Bulgaria, Colombia, Hungary, Ukraine
Astellas Pharma Global Development, Inc.

Completed

A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K

Healthy Volunteers | Pharmacokinetics of ASP015K | Food Effect

United States
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate

Rheumatoid Arthritis | Pharmacokinetics of ASP2409

United States
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects

Healthy Subjects | Pharmacokinetics of ASP2408

United States
Astellas Pharma Global Development, Inc.

Completed

A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate

Rheumatoid Arthritis | Pharmacokinetics of ASP2408

United States
Astellas Pharma Global Development, Inc.

Completed

Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects

Healthy Volunteers

United States
Nuvectis Pharma, Inc.

Recruiting

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

Advanced Solid Tumor

United States, United Kingdom
Aneira Pharma, Inc.

Recruiting

Proof of Concept Study of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation

Hypotrichosis

United States
Vincerx Pharma, Inc.

Recruiting

Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

Neoplasms

Australia, United States
Kringle Pharma, Inc.

Recruiting

Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury

Acute Spinal Cord Injury

Japan
OBI Pharma, Inc

Recruiting

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Triple Negative Breast Cancer

China, Taiwan, United States, Korea, Republic of, Australia, Brazil, Hong Kong, Mexico, Russian Federation, South Africa, Ukraine, Peru, Poland
MEI Pharma, Inc.

Recruiting

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Acute Myeloid Leukemia (AML) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL)

United States
Astellas Pharma Inc

Active, not recruiting

A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy (MOUNTAINSIDE)

Primary Mitochondrial Myopathy

United States
Astellas Pharma Inc

Completed

A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Gastric Cancer | Gastro-esophageal Junction (GEJ) Cancer

Japan
MEI Pharma, Inc.

Active, not recruiting

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Colorectal Cancer

United States
Inversago Pharma Inc.

Active, not recruiting

Study of INV-202 in Patients With Obesity and Metabolic Syndrome

Obesity | Metabolic Syndrome

Canada
OBI Pharma, Inc

Terminated

This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.

Locally Advanced Solid Tumors | Metastatic Solid Tumors

United States, Taiwan
aTyr Pharma, Inc.

Completed

Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) (FSHD)

Limb-Girdle Muscular Dystrophies | Facioscapulohumeral Muscular Dystrophy

United States, Denmark, France
aTyr Pharma, Inc.

Completed

Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy (FSHD)

Facioscapulohumeral Muscular Dystrophy (FSHD)

United States, France, Italy
Astellas Pharma Inc

Terminated

A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy (DMD)

United States
Ocuphire Pharma, Inc.

Completed

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma

Ocular Hypertension | Open Angle Glaucoma

United States
Acasti Pharma Inc.

Completed

Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects

Aneurysmal Subarachnoid Hemorrhage

Canada
Ocuphire Pharma, Inc.

Completed

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

Mydriasis | Dilation

United States
aTyr Pharma, Inc.

Completed

Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension

Facioscapulohumeral Muscular Dystrophy

United States, Italy, Netherlands
Sinew Pharma Inc.

Completed

Phase I Pharmacokinetic Study of HUYPS-1 in Healthy Volunteers

Nonalcoholic Steatohepatitis

Taiwan
Ocuphire Pharma, Inc.

Active, not recruiting

Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia (VEGA-2)

Presbyopia

United States
Yuyu Pharma, Inc.

Active, not recruiting

Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)

Dry Eye

United States
Astellas Pharma Inc

Completed

Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors

Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies

Japan
Ocuphire Pharma, Inc.

Completed

Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy (ZETA-1)

Diabetic Retinopathy | Diabetic Macular Edema | NPDR - Non Proliferative Diabetic Retinopathy | PDR - Proliferative Diabetic Retinopathy

United States
Akros Pharma Inc.

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Sinew Pharma Inc.

Terminated

An Open-Label Study to Assess the Hepatic Protection Effect of SNP-612, in Patients With NAFLD

NASH - Nonalcoholic Steatohepatitis

Taiwan
FSD Pharma, Inc.

Terminated

Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19

COVID-19

United States
Inversago Pharma Inc.

Completed

A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome

Metabolic Syndrome

Canada
OBI Pharma, Inc

Completed

Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects

Metastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric Cancer

Taiwan
Astellas Pharma Inc

Completed

A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes

Bipolar Disorder

Japan
Tris Pharma, Inc.

Completed

Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic

Diabetic Polyneuropathy

Germany, United Kingdom
Tris Pharma, Inc.

Terminated

CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer (CORAL)

Neoplasms | Pain | Chronic Pain

Croatia, Austria, Belgium, Bulgaria, Denmark, Germany, Hungary, Poland, Romania, Serbia, Slovakia, Chile, Spain, United Kingdom
Inversago Pharma Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects

Pharmacokinetic

Canada
Astellas Pharma Inc

Completed

Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors

Advanced Solid Tumors

Japan
Beta Pharma, Inc.

Completed

A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711

NSCLC

China
Cocrystal Pharma, Inc.

Completed

A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects

Hepatitis C

Canada
Medexus Pharma, Inc.

Terminated

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B

Hemophilia B

United States, United Kingdom, India
Astellas Pharma Inc

Completed

A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015K

Arthritis, Rheumatoid

Japan, Korea, Republic of, Taiwan
Tris Pharma, Inc.

Completed

TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity

United States
Astellas Pharma Inc

Completed

A Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia

Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis

Japan
Acanthas Pharma Inc

Withdrawn

A Study of Single Ascending Doses of STAR-101 in Healthy Participants

Healthy Volunteers
Astellas Pharma Inc

Completed

Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome With Constipation (IBS-C)

Japan
Astellas Pharma Inc

Completed

A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

Ovarian Cancer | Solid Tumors

United States, United Kingdom, Australia, Canada, Switzerland, Czechia, Italy, Poland, Romania, Russian Federation
Astellas Pharma Inc

Completed

A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

Advanced Solid Tumors

United States, United Kingdom

3

Subscribe